Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PODD 
Insulet Corporation (PODD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: PODD (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
23 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $328.73
Year Target Price $328.73
| 14 | Strong Buy |
| 6 | Buy |
| 2 | Hold |
| 0 | Under performing |
| 1 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 26.17% | Avg. Invested days 58 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 22.03B USD | Price to earnings Ratio 56.51 | 1Y Target Price 336.01 |
Price to earnings Ratio 56.51 | 1Y Target Price 336.01 | ||
Volume (30-day avg) - | Beta 1.38 | 52 Weeks Range 173.00 - 329.33 | Updated Date 06/29/2025 |
52 Weeks Range 173.00 - 329.33 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 5.54 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 18.29% | Operating Margin (TTM) 15.61% |
Management Effectiveness
Return on Assets (TTM) 6.94% | Return on Equity (TTM) 37.92% |
Valuation
Trailing PE 56.51 | Forward PE 76.34 | Enterprise Value 22445280892 | Price to Sales(TTM) 10.02 |
Enterprise Value 22445280892 | Price to Sales(TTM) 10.02 | ||
Enterprise Value to Revenue 10.21 | Enterprise Value to EBITDA 53.66 | Shares Outstanding 70374896 | Shares Floating 70063866 |
Shares Outstanding 70374896 | Shares Floating 70063866 | ||
Percent Insiders 0.29 | Percent Institutions 102.73 |
Analyst Ratings
Rating 4.43 | Target Price 328.73 | Buy 6 | Strong Buy 14 |
Buy 6 | Strong Buy 14 | ||
Hold 2 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Insulet Corporation
Company Overview
History and Background
Insulet Corporation was founded in 2000. It is focused on simplifying diabetes management through innovative technology, notably the Omnipod Insulin Management System. It has grown significantly over the years, focusing on product innovation and market expansion.
Core Business Areas
- Insulin Delivery Systems: Insulet's primary business revolves around the design, development, manufacture, and marketing of the Omnipod Insulin Management System, a tubeless insulin pump.
Leadership and Structure
The leadership team includes Jim Hollingsworth (CEO). The organizational structure is typical of a publicly traded medical device company, with departments covering research and development, manufacturing, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- Omnipod Insulin Management System: The Omnipod is a tubeless, wearable insulin pump. Market share is estimated around 25%. Competitors include Medtronic (MDT), Tandem Diabetes Care (TNDM), and traditional insulin pens and syringes. Revenue is primarily derived from Omnipod sales and related supplies. The Omnipod 5 is their newest system.
Market Dynamics
Industry Overview
The insulin delivery market is growing due to the increasing prevalence of diabetes and advancements in technology. Demand is rising for convenient and user-friendly insulin delivery systems.
Positioning
Insulet is positioned as an innovator in the insulin delivery market, particularly with its tubeless Omnipod system. Their competitive advantage lies in the convenience and ease of use of the Omnipod.
Total Addressable Market (TAM)
The global insulin delivery market is projected to reach multi-billion dollars. Insulet is positioned well to capture a significant portion of this TAM with its innovative Omnipod system targeting a large segment of insulin-dependent individuals.
Upturn SWOT Analysis
Strengths
- Innovative product (Omnipod)
- Tubeless design for user convenience
- Strong brand reputation
- Growing market share
- Direct-to-consumer sales model
Weaknesses
- Reliance on a single product line
- High manufacturing costs
- Competition from established players
- Dependence on third-party insulin
- Product recall history
Opportunities
- Expansion into new geographic markets
- Development of new Omnipod features and versions
- Partnerships with diabetes management companies
- Integration with continuous glucose monitoring (CGM) systems
- Expansion into automated insulin delivery (AID) systems
Threats
- Competition from Medtronic and Tandem
- Pricing pressures from insurers
- Regulatory changes
- Technological advancements by competitors
- Potential product liability lawsuits
Competitors and Market Share
Key Competitors
- MDT
- TNDM
Competitive Landscape
Insuletu2019s advantage is its tubeless technology. Medtronic has a larger market presence. Tandem Diabetes Care focuses on advanced automated insulin delivery systems.
Growth Trajectory and Initiatives
Historical Growth: Insulet has experienced significant growth in revenue due to increased adoption of the Omnipod system.
Future Projections: Analyst estimates project continued revenue growth for Insulet, driven by new product launches and market expansion.
Recent Initiatives: Recent initiatives include the launch of the Omnipod 5 and expansion into new international markets.
Summary
Insulet is a strong company with an innovative product that is gaining market share. The Omnipod's tubeless design differentiates it. They face competition from larger, more established players and need to manage manufacturing costs effectively to maintain profitability and continue growing.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data are estimates and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Insulet Corporation
Exchange NASDAQ | Headquaters Acton, MA, United States | ||
IPO Launch date 2007-05-15 | CEO, President & Director Ms. Ashley A. McEvoy | ||
Sector Healthcare | Industry Medical Devices | Full time employees 3900 | Website https://www.insulet.com |
Full time employees 3900 | Website https://www.insulet.com | ||
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.